Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.

Choosing between KB and PG solutions for applying RU58841, considering factors like scalp oiliness and absorption. Some users prefer KB for being gentler, while others use PG and recommend washing hair before application for better results.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.

User tried Pyrilutamide for hair loss and noticed less hair fall initially, but experienced more hair fall after four days. Others advised to assess results after a longer period and consider increasing dosage for better results.

The user is seeking advice on adding CB 03-01 to their hair loss treatment, which includes RU58841, Fluridil, Minoxidil, and Pantostin, but cannot use finasteride.

The user experienced hair regrowth using a combination of Minoxidil, Finasteride, and RU58841, with Minoxidil used initially and the other treatments added later. The user believes the combination of Finasteride and RU58841 contributed to the regrowth, with RU sourced from MVsupplement.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

Purchasing Pyrilutamide for hair loss treatment in India, and exploring the possibility of utilizing Minoxidil, Finasteride, and RU58841 as alternatives.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The conversation discusses using RU58841 for hair loss, with OP experiencing thinning in the front area and steady hair loss. OP plans to try microneedling while avoiding finasteride and dutasteride.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

RU58841 is discussed as a potential treatment for acne and hair loss, with users debating its effectiveness and safety compared to other treatments like finasteride, minoxidil, and dutasteride. Concerns about RU58841's side effects and lack of clinical trials are raised, while some users share their personal experiences and routines involving RU58841 for hair loss.

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

User discusses Pyrilutamide's effectiveness for hair loss, needing more time for results. Others suggest waiting 6-12 months and ask about side effects.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.